Objective: The aim of the present study was to investigate the relationship among serum mean platelet volume (MPV) levels, benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and metabolic syndrome (MetS), and study the potential role of serum MPV levels in BPH/LUTS progression in an indirect manner. Methods: Five hundred fifty-one men aged 45 or older with moderate to severe LUTS due to benign prostatic enlargement were recruited into this study by consecutive routine physical examination programs. Urologic evaluation included transrectal ultrasound, International Prostate Symptom Score and maximum urinary flow rate (Qmax). Overnight fasting venous blood specimens were collected and serum levels of prostate-specific antigen, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglyceride and C-reactive protein (CRP) were recorded. In addition, MPV were determined by automated hematology analyzer. We divided subjects into 2 groups according to the presence of MetS. We also took the MPV values as a categorical variable and divided subjects into 2 groups (≥11.8 or <11.8 fl) or 4 groups according to the different levels of MPV (9.3-11.0, 11.1-11.5, 11.6-11.9, 12.0-12.5 and ≥12.5 fl). The clinical characteristics and parameters of BPH/LUTS in different groups were measured and compared to identify their relationships. Results: MetS was diagnosed in 37.0% of the subjects. There were significant interactive correlation among the number of positive MetS components, CRP, MPV and parameters of BPH/LUTS. The ratio of PV ≥31 ml and Qmax <10.6 ml/s were positively correlated with the increased level of MPV. Additionally, the OR in relation to PV ≥31 ml and Qmax <10.6 ml/s significantly rose as the level of MPV increased after adjusting for age, suggesting of a threshold effect at 12.0-12.5 fl for PV ≥31 ml (OR 2.678, 95% CI 1.425-5.035) and at >12.5 fl for Qmax <10.6 ml/s (OR 3.190, 95% CI 1.768-5.755). However, only the value of MPV more than 12.5 fl still showed statistically significant effect on Qmax <10.6 ml/s after adjusting for age and the presence of MetS (OR 2.164, 95% CI 1.162-4.032). Conclusions: Our results add to the evidence that chronic inflammation is a candidate mechanism at the crossroad between MetS and BPH/LUTS, and the presence of elevated MPV may serve as a predictor of MetS-induced inflammation in the progression of BPH/LUTS.

Keywords:
Lower urinary tract symptoms, Benign prostatic hyperplasia, Metabolic syndrome, Inflammation, Mean platelet volume
1.
Abrams P: LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev Urol 1999;1:65.
2.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; And International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
3.
Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH: The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82:674-679.
4.
Pan JG, Jiang C, Luo R, Zhou X: Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int 2014;93:10-16.
5.
Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X: Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93:214-219.
6.
Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M: Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-106.
7.
He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S: Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 2015, Epub ahead of print.
8.
Varol E, Akcay S, Ozaydin M, Erdogan D, Dogan A, Altinbas A: Mean platelet volume is associated with insulin resistance in non-obese, non-diabetic patients with coronary artery disease. J Cardiol 2010;56:154-158.
9.
Lancé MD, Sloep M, Henskens YM, Marcus MA: Mean platelet volume as a diagnostic marker for cardiovascular disease: drawbacks of preanalytical conditions and measuring techniques. Clin Appl Thromb Hemost 2012;18:561-568.
10.
Al-Mallah MH, Nasir K, Katz R, Takasu J, Lima JA, Bluemke DA, Hundley G, Blumenthal RS, Budoff MJ: Thoracic aortic distensibility and thoracic aortic calcium (from the multi-ethnic study of atherosclerosis [MESA]). Am J Cardiol 2010;106:575-580.
11.
Wang RT, Li Y, Zhu XY, Zhang YN: Increased mean platelet volume is associated with arterial stiffness. Platelets 2011;22:447-451.
12.
Han JS, Park TS, Cho SY, Joh JH, Ahn HJ: Increased mean platelet volume and mean platelet volume/platelet count ratio in Korean patients with deep vein thrombosis. Platelets 2013;24:590-593.
13.
Cho SY, Suh JS, Cho BS, Lee WI, Lee HJ, Suh JT, Park TS: Mean platelet volume in pediatric chronic kidney diseases. Platelets 2013;24:164-165.
14.
Bath PM, Missouris CG, Buckenham T, MacGregor GA: Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci (Lond) 1994;87:253-257.
15.
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD: Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58.
16.
Badía X, García-Losa M, Dal-Ré R: Ten-language translation and harmonization of the international prostate symptom score: developing a methodology for multinational clinical trials. Eur Urol 1997;31:129-140.
17.
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG; MTOPS Research Group: Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-1426.
18.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Lockwood G, Sykes J, Kwast Tv: Prevalence of inflammation and benign prostatic hyperplasia on autopsy Asian and Caucasian men. Eur Urol 2014;66:619-622.
19.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009;69:1774-1780.
20.
Torkko KC, Wilson RS, Smith EE, Kusek JW, van Bokhoven A, Lucia MS: Prostate biopsy markers of Inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J Urol 2015;194:454-461.
21.
Gustafson B, Hammarstedt A, Andersson CX, Smith U: Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276-2283.
22.
Lepor H: Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004;6(suppl 9):S3-S10.
23.
Summah H, Qu JM: Biomarkers: a definite plus in pneumonia. Mediators Inflamm 2009;2009:675-753.
24.
Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, Wei Q: Evaluation of Interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009;74:340-344.
25.
Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F: The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 2014;15:463-468.
26.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F: The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-441.
27.
Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR: Platelet size and age determine platelet function independently. Blood 1984;63:1372-1375.
28.
Gear AR, Camerini D: Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003;10:335-350.
29.
Weyrich AS, Lindemann S, Zimmerman GA: The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897-1905.
30.
Coban E, Ozdogan M, Yazicioglu G, Akcit F: The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59:981-982.
31.
Coban E, Bostan F, Ozdogan M: The mean platelet volume in subjects with impaired fasting glucose. Platelets 2006;17:67-69.
32.
Hekimsoy Z, Payzin B, Ornek T, Kandoğan G: Mean platelet volume in type 2 diabetic patients. J Diabetes Complications 2004;18:173-176.
33.
Coban E, Afacan B: The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 2008;19:111-114.
34.
Ozhan H, Aydin M, Yazici M, Yazgan O, Basar C, Gungor A, Onder E: Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets 2010;21:29-32.
35.
Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A: Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007;120:245-250.
36.
Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H: Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720-2725.
37.
Vizioli L, Muscari S, Muscari A: The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009;63:1509-1515.
38.
Abdel-Razik A, Eldars W, Rizk E: Platelet indices and inflammatory markers as diagnostic predictors for ascitic fluid infection. Eur J Gastroenterol Hepatol 2014;26:1342-1347.
39.
Debili N, Massé JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W: Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993;82:84-95.
40.
Peehl DM, Cohen P, Rosenfeld RG: The role of insulin-like growth factors in prostate biology. J Androl 1996;17:2-4.
41.
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR: Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 2008;68:1477-1486.
42.
Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L: The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009;69:480-493.
43.
Coffey DS: Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology 2001;57(4 suppl 1):31-38.
44.
Cantiello F, Cicione A, Salonia A, Autorino R, Ucciero G, Tucci L, Briganti A, Damiano R: Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy. Int J Urol 2014;21:264-269.
45.
Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M: Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008;75:291-294.
46.
Kiliçli-Camur N, Demirtunç R, Konuralp C, Eskiser A, Başaran Y: Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit 2005;11:CR387-CR392.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.